RxDoctor Payments Data

Shannon Foster, MD

Family Medicine · Winchester, TNNPI 1174849889

Payments from drug & device makers

$379in general payments, 2019–2025

Across 11 payments — averaging $34.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$273
  • Novo Nordisk$58
  • Lundbeck LLC$18
  • AstraZeneca$16
  • Eisai Inc.$14

What the payments were for

  • Food & beverage$379100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie5$273
Novo Nordisk3$58
Lundbeck LLC1$18
AstraZeneca1$16
Eisai Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$379 in reported general payments places this provider in the 45th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$176,923
Medicare patients
331
Services billed
2,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide207$250,173
EliquisApixaban96$101,339
JardianceEmpagliflozin90$99,141
RybelsusSemaglutide60$91,509
MounjaroTirzepatide67$79,280
FarxigaDapagliflozin Propanediol40$47,550
XareltoRivaroxaban40$46,223
TrulicityDulaglutide33$42,141
JanuviaSitagliptin Phosphate28$38,822
Tresiba Flextouch U-100Insulin Degludec29$25,975
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$21,831
TradjentaLinagliptin17$18,486
LinzessLinaclotide18$18,468
JanumetSitagliptin Phos/Metformin Hcl11$9,128
Rosuvastatin Calcium501$8,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$58$341,682267 claims
AstraZenecaFarxiga$16$47,55040 claims
AbbVieLinzess$273$18,46818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Winchester

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →